Literature DB >> 24121152

Combined restitutive therapy for treatment of immunosuppressive refractory Crohn disease.

Jason R Goldsmith1, Maureen Kelly, Katherine B Freeman, Debora Duro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 24121152      PMCID： PMC3981954          DOI： 10.1097/MPG.0000000000000191

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN： 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  9 in total

1.  Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.

Authors:  Edward V Loftus
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

2.  Sargramostim for active Crohn's disease.

Authors:  Joshua R Korzenik; Brian K Dieckgraefe; John F Valentine; Diana F Hausman; Mark J Gilbert
Journal:  N Engl J Med       Date:  2005-05-26       Impact factor: 91.245

3.  Low-dose naltrexone therapy improves active Crohn's disease.

Authors:  Jill P Smith; Heather Stock; Sandra Bingaman; David Mauger; Moshe Rogosnitzky; Ian S Zagon
Journal:  Am J Gastroenterol       Date:  2007-01-11       Impact factor: 10.864

Review 4.  Microbial influences in inflammatory bowel diseases.

Authors:  R Balfour Sartor
Journal:  Gastroenterology       Date:  2008-02       Impact factor: 22.682

5.  Intestinal epithelial cell-derived μ-opioid signaling protects against ischemia reperfusion injury through PI3K signaling.

Authors:  Jason R Goldsmith; Ernesto Perez-Chanona; Prem N Yadav; Jennifer Whistler; Bryan Roth; Christian Jobin
Journal:  Am J Pathol       Date:  2013-01-02       Impact factor: 4.307

Review 6.  Treatment of inflammatory bowel disease (IBD).

Authors:  Anand B Pithadia; Sunita Jain
Journal:  Pharmacol Rep       Date:  2011       Impact factor: 3.024

7.  Phase I trial of sargramostim in pediatric Crohn's disease.

Authors:  Judith R Kelsen; Joel Rosh; Mel Heyman; Harland S Winter; George Ferry; Stanley Cohen; Petar Mamula; Robert N Baldassano
Journal:  Inflamm Bowel Dis       Date:  2010-07       Impact factor: 5.325

8.  Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.

Authors:  Tally M Largent-Milnes; Wenhong Guo; Hoau-Yan Wang; Lindsay H Burns; Todd W Vanderah
Journal:  J Pain       Date:  2008-05-12       Impact factor: 5.820

Review 9.  Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease.

Authors:  Arthur Kaser; Richard S Blumberg
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682
  9 in total
  2 in total

1.  Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study.

Authors:  T Ringel-Kulka; J R Goldsmith; I M Carroll; S P Barros; O Palsson; C Jobin; Y Ringel
Journal:  Aliment Pharmacol Ther       Date:  2014-05-22       Impact factor: 8.171

Review 2.  Current overview of opioids in progression of inflammatory bowel disease; pharmacological and clinical considerations.

Authors:  Naser-Aldin Lashgari; Nazanin Momeni Roudsari; Nadia Zandi; Benyamin Pazoki; Atiyeh Rezaei; Mehrnoosh Hashemi; Saeideh Momtaz; Roja Rahimi; Maryam Shayan; Ahmad Reza Dehpour; Amir Hossein Abdolghaffari
Journal:  Mol Biol Rep       Date:  2021-01-04       Impact factor: 2.316
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.